New effective chemically synthesized anti-smallpox compound NIOCH-14

Area of Science:

• Virology
• Medicinal Chemistry
• Pharmacology

Background:

• Orthopoxviruses pose significant public health threats, necessitating the development of novel antiviral therapies.
• Existing treatments have limitations, driving the search for effective alternatives against highly pathogenic strains.

Purpose of the Study:

• To evaluate the antiviral efficacy of a novel compound, NIOCH-14, against orthopoxviruses.
• To compare the activity of NIOCH-14 with the established antiviral ST-246 in vitro and in vivo.
• To assess the therapeutic window and safety profile of NIOCH-14.

Main Methods:

• In vitro and in vivo antiviral assays using various orthopoxviruses (ectromelia, monkeypox, variola).
• Oral administration of NIOCH-14 and ST-246 to infected animal models (ICR mice, SCID mice, marmots).
• Quantification of viral titers, assessment of pathological changes, and survival rates.

Main Results:

• NIOCH-14 demonstrated comparable 50% effective doses to ST-246 against ectromelia virus.
• Both compounds significantly reduced viral loads and pathological lung changes in infected mice and marmots.
• A broad therapeutic window was observed for NIOCH-14, extending from before infection to days post-infection.

Conclusions:

• NIOCH-14 exhibits significant antiviral activity against a range of orthopoxviruses, including highly pathogenic strains.
• The compound shows promise as a potential therapeutic agent for diseases caused by orthopoxviruses.
• Further research into NIOCH-14 is warranted for the development of a new smallpox drug.